Eli Lilly and Company $LLY Shares Acquired by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. lifted its stake in Eli Lilly and Company (NYSE:LLY) by 7.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,689 shares of the company’s stock after buying an additional 2,976 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Eli Lilly and Company were worth $49,991,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of LLY. BlackRock Inc. grew its holdings in shares of Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after purchasing an additional 1,046,558 shares during the last quarter. State Street Corp lifted its holdings in shares of Eli Lilly and Company by 1.7% in the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after purchasing an additional 605,752 shares during the last quarter. Capital World Investors lifted its holdings in shares of Eli Lilly and Company by 0.4% in the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after purchasing an additional 61,851 shares during the last quarter. Norges Bank acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $12,976,634,000. Finally, Bank of America Corp DE acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at about $13,522,666,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

LLY traded down $16.45 on Wednesday, hitting $1,153.69. 2,153,958 shares of the company traded hands, compared to its average volume of 3,016,686. Eli Lilly and Company has a 12-month low of $712.05 and a 12-month high of $1,292.65. The company has a 50 day moving average of $1,176.84 and a 200-day moving average of $1,079.50. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The stock has a market capitalization of $1.09 trillion, a PE ratio of 38.71, a PEG ratio of 1.44 and a beta of 0.50.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company’s revenue was up 47.7% on a year-over-year basis. During the same period last year, the business posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 36.54 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Leerink Partners raised their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. UBS Group set a $1,376.00 price objective on Eli Lilly and Company in a report on Friday, August 7th. Berenberg Bank set a $1,400.00 target price on shares of Eli Lilly and Company and gave the stock a “buy” rating in a research report on Tuesday, September 15th. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. Finally, TD Cowen reiterated a “buy” rating and issued a $1,250.00 price target on shares of Eli Lilly and Company in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,305.25.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 in the last three months. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CEO Dave Ricks said Lilly is capturing about 70% of new senior GLP-1 patients following Medicare coverage expansion, while oral GLP-1 drug Foundayo accounts for roughly one-third of new oral-treatment starts. The comments reinforce Lilly’s commercial leadership and suggest that expanded insurance coverage could materially enlarge the addressable market. Lilly CEO discusses Medicare GLP-1 market share
• Positive Sentiment: Lilly broke ground on a $6.5 billion Houston manufacturing facility that will produce active ingredients for Foundayo and other medicines. The investment supports the company’s planned oral GLP-1 rollout, strengthens domestic supply, and is expected to create more than 600 jobs, although the benefits will take time to materialize. Lilly Houston manufacturing facility
• Positive Sentiment: Investors remain bullish on Lilly’s long-term growth. Home Depot co-founder Ken Langone said the shares could reach $2,000 within three to four years, reflecting confidence in the company’s obesity portfolio and broader pipeline. Ken Langone bullish on Lilly
• Neutral Sentiment: Lilly received full FDA approval for Inluriyo in combination with Verzenio for advanced ESR1-mutated breast cancer, adding support to its oncology franchise. The approval is strategically positive but likely less important to near-term valuation than the obesity business. Inluriyo FDA approval
• Negative Sentiment: Viking Therapeutics reported data indicating its VK2735 obesity drug preserved most weight loss with every-other-week or monthly dosing. The result drove strong interest in a potential competitor to Zepbound, raising concerns about future pricing, adherence, and market-share pressure for Lilly, although Viking still needs Phase 3 results and regulatory approval. Viking obesity drug maintenance data
• Negative Sentiment: Novo Nordisk’s CagriSema also produced favorable late-stage weight-loss data in a diabetes study, keeping competitive pressure high. Lilly’s $6.5 billion facility further increases near-term capital spending, which may temper enthusiasm despite strong long-term demand.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.